Rallybio Corp

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

RLYB$15.76+0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Cash Flows

	FOR THE THREE MONTHS ENDED MARCH 31,
(in thousands)	2025	2024
Cash Flows Used in Operating Activities:
Net loss	$(9,439)	$(19,029)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	28	35
Net accretion of discounts/premiums on debt securities	(210)	(539)
Share-based compensation	1,879	2,088
Loss on investment in joint venture	587	685
Changes in operating assets and liabilities:
Prepaid expenses, operating lease right-of-use assets and other current assets	(506)	537
Accounts payable	122	(506)
Accrued expenses and operating lease liabilities	(2,454)	1,272
Deferred revenue	(212)	—
Net cash used in operating activities	(10,205)	(15,457)
Cash Flows Provided by Investing Activities:
Purchases of marketable securities	(5,919)	(10,736)
Proceeds from maturities of marketable securities	18,000	21,750
Investment in joint venture	(1,000)	(750)
Net cash provided by investing activities	11,081	10,264
Cash Flows Provided by Financing Activities:
Net cash provided by financing activities	—	—
Net increase (decrease) in cash and cash equivalents	876	(5,193)
Cash and cash equivalents — beginning of period	13,903	24,494
Cash and cash equivalents — end of period	$14,779	$19,301

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.